poisar

Stocks · News reference

Evaxion Expands Pipeline Of Cancer Vaccine Programs With EVX-05 Against Deadly Brain Cancer Glioblastoma

Benzinga Newsdesk

EVX-05 is an off-the-shelf therapeutic glioblastoma (brain cancer) vaccine designed based on patient tumor samples. It targets novel conserved antigens identified using Evaxion’s AI-Immunology™ platformGlioblastoma is

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

EVAX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

    Evaxion will present new immune profiling data from its phase 2 trial of personalized cancer vaccine EVX-01 combined with pembrolizumab at the SITC 2026 Annual Meeting in November. The data will showcase systemic immunomodulatory effects beyond vaccine-specific T-cell responses. Previous two-year data showed a 75% objective response rate in advanced melanoma patients, with 92% still responding at two-year follow-up and no relapses observed.

    MRKEVAX
  3. Benzinga Insights

    Evaxion Biotech Q2 2026 Earnings Call: Complete Transcript

    On Thursday, Evaxion Biotech (NASDAQ:EVAX) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive

    EVAX
  4. Benzinga Newsdesk

    Evaxion Biotech Q2 EPS $(0.01) Beats $(0.31) Estimate

    Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.31) by 96.77 percent. This is a 50 percent increase over losses of $(0.02) per share from the

    EVAX